About us
Starting a century ago, CSL Behring made a promise to save lives and protect the health of people stricken with a range of serious and chronic medical conditions. Today that same promise has never been stronger. CSL Behring is part of the CSL Group, which has more than 25,000 employees and does business in 60+ countries. CSL Behring develops and delivers biotherapies for people with life-threatening medical conditions. Our broad range of therapies includes those to treat disorders such as hemophilia and primary immune deficiencies. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge, and support future medical research. Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enables us to accurately identify, successfully develop, and dependably deliver innovations that patients and providers want. For a century, CSL Behring has earned a reputation as a passionate yet responsible organization, driven to care for patients and deliver on its commitments.
Forbes magazine has named global biotechnology leader CSL Limited as one of the best employers for diversity in the United States. CSL, the fifth largest biotechnology company in the world, ranked No. 39 in the leading business magazine’s annual list of the best 500 employers for diversity. This achievement reflects CSL’s focus to build a workplace culture where employees have a promising future and can fulfill their career aspirations, realize their potential, and be part of a purpose-driven company that focuses on saving and protecting the lives of people around the world. In 2018, Forbes ranked CSL as one of the top 50 employers in the world and Thomson Reuters included CSL in its top 100 global diversity and inclusion index.